The methionine aminopeptidase 2 inhibitor, TNP-470, enhances the antidiabetic properties of sitagliptin in mice by upregulating xenin

Ψ-xenin-6 enhances sitagliptin effectiveness, but does not improve glucose tolerance

(2020) Sarah L Craig et al.   JOURNAL OF ENDOCRINOLOGY

Function and mechanisms of enteroendocrine cells and gut hormones in metabolism

(2019) Fiona M. Gribble et al.   Nature Reviews Endocrinology

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study

(2019) Natasha C. Bergmann et al.   DIABETOLOGIA

Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential

(2019) Marie Bastin et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Peptide YY (1–36) peptides from phylogenetically ancient fish targeting mammalian neuropeptide Y1 receptors demonstrate potent effects on pancreatic β‐cell function, growth and survival

(2019) Ryan A. Lafferty et al.   DIABETES OBESITY & METABOLISM

Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential

(2018) N.M. Pathak et al.   BIOCHEMICAL PHARMACOLOGY

Emerging therapeutic potential for xenin and related peptides in obesity and diabetes

(2018) Sarah L. Craig et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Emerging therapeutic potential for peptide YY for obesity-diabetes

(2018) Ryan A. Lafferty et al.   PEPTIDES

A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice

(2018) Annie Hasib et al.   PEPTIDES

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

(2018) Juan Pablo Frias et al.   LANCET

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

(2018) Tamer Coskun et al.   Molecular Metabolism

Central action of xenin affects the expression of lipid metabolism-related genes and proteins in mouse white adipose tissue

(2017) Sharma Bhavya et al.   NEUROPEPTIDES

Enhanced insulin sensitivity in successful, long-term weight loss maintainers compared with matched controls with no weight loss history

(2017) L D Clamp et al.   Nutrition & Diabetes

A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing properties

(2016) Vadivel Parthsarathy et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Biological Activity and Antidiabetic Potential of C-Terminal Octapeptide Fragments of the Gut-Derived Hormone Xenin

(2016) Christine M. Martin et al.   PLoS One

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline

(2015) V. A. Gault et al.   DIABETES OBESITY & METABOLISM

The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice

(2015) Gunnar Sørensen et al.   PHYSIOLOGY & BEHAVIOR

N-terminal modifications of cellular proteins: The enzymes involved, their substrate specificities and biological effects

(2015) Sylvia Varland et al.   PROTEOMICS

Xenin-25[Lys13PAL]: a novel long-acting acylated analogue of xenin-25 with promising antidiabetic potential

(2014) V. A. Gault et al.   ACTA DIABETOLOGICA

Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors

(2014) B. Omar et al.   DIABETES

Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors

(2014) K. Aaboe et al.   DIABETES OBESITY & METABOLISM

Characterisation of the biological activity of xenin-25 degradation fragment peptides

(2014) Christine M A Martin et al.   JOURNAL OF ENDOCRINOLOGY

Role of Endogenous GLP-1 and GIP in Beta Cell Compensatory Responses to Insulin Resistance and Cellular Stress

(2014) Srividya Vasu et al.   PLoS One

Adipokines and insulin action

(2014) Alexander J Knights et al.   Adipocyte

Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity

(2014) Amit Joharapurkar et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without Type 2 diabetes

(2013) Sara Chowdhury et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents

(2013) K. Tatarkiewicz et al.   DIABETES OBESITY & METABOLISM

Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25

(2012) Christine M.A. Martin et al.   BIOCHEMICAL PHARMACOLOGY

The use of animal models in diabetes research

(2012) Aileen JF King   BRITISH JOURNAL OF PHARMACOLOGY

Xenin-25 Amplifies GIP-Mediated Insulin Secretion in Humans With Normal and Impaired Glucose Tolerance but Not Type 2 Diabetes

(2012) B. M. Wice et al.   DIABETES

The Angiogenic Inhibitor TNP-470 Decreases Caloric Intake and Weight Gain in High-Fat Fed Mice

(2012) Heather M. White et al.   Obesity

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes

(2011) J. J. Holst et al.   DIABETES CARE

Study of the Potential Association of Adipose Tissue GLP-1 Receptor with Obesity and Insulin Resistance

(2011) Joan Vendrell et al.   ENDOCRINOLOGY

GLP-1 and energy balance: an integrated model of short-term and long-term control

(2011) Jason G. Barrera et al.   Nature Reviews Endocrinology

Xenin-25 Potentiates Glucose-dependent Insulinotropic Polypeptide Action via a Novel Cholinergic Relay Mechanism

(2010) Burton M. Wice et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety

(2010) Ashley I Taylor et al.   JOURNAL OF ENDOCRINOLOGY

Fumagillin Reduces Adipose Tissue Formation in Murine Models of Nutritionally Induced Obesity

(2010) Henri R. Lijnen et al.   Obesity

GIP and GLP-1, the two incretin hormones: Similarities and differences

(2010) Yutaka Seino et al.   Journal of Diabetes Investigation

Therapeutic potential for GIP receptor agonists and antagonists

(2009) Nigel Irwin et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Central and Peripheral Regulation of Food Intake and Physical Activity: Pathways and Genes

(2008) Natalie R. Lenard et al.   Obesity